Commentary|Podcasts|August 3, 2023

Pharma Marketing in the Age of AI: A New Era Begins

This podcast companion to our roundtable feature explores the transformative power of AI in pharmaceutical marketing, six months after the arrival of ChatGPT.

In this podcast, Sharlene Jenner, vice president of engagement strategy at Abelson Taylor and professor of AI and personalization for digital marketers at Southern Methodist University, leads a panel of five industry leaders in a roundtable discussion. The conversation delves into the practicalities of current AI applications and confronts the ethical and regulatory issues related to thetechnology. The panelists also explore the direct consequences and prospective implications of AI, providing listeners with a snapshot of the present and an outlook on the transformative potential of emerging technologies in the pharmaceutical marketing sphere.

Sponsor

https://www.zs.com/

About the speakers

The moderator, Sharlene Jenner, is the vice president of engagement strategy, AbelsonTaylor, and professor, Southern Methodist University, artificial intelligence and personalization for digital marketers.

The panel consists of:

  • Faruk Capan, chief innovation officer, EVERSANA, and CEO, EVERSANA INTOUCH
  • Anurag Banerjee, CEO and founder, Quilt.AI
  • Jeff Headd, vice president, commercial data science, The Janssen Pharmaceutical Companies of Johnson & Johnson
  • Stephen Onikoro, senior principal, head of strategy, PharmaForceIQ

About the Pharm Exec Podcast

The editors of Pharmaceutical Executive brings you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.

Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.